Vinod K. Khetarpal

Preclinical evaluation of CHDI-009R for quantification of mutant huntingtin aggregates

This study evaluates [11C]CHDI-009R as a PET radioligand for quantifying mutant huntingtin aggregates in a mouse model of HD, showing high stability, reliability, and genotype differentiation.

mTOR inhibition in Q175 Huntington's disease model mice facilitates neuronal autophagy and mutant huntingtin clearance

This study shows that mTOR inhibition in HD model mice improves autophagy and reduces mutant huntingtin accumulation.

Preclinical validation and kinetic modelling of the SV2A PET ligand UCB-J in mice

The paper validates [18F]UCB-J as a selective SV2A PET ligand in mice, showing reliable kinetics and volume of distribution measurements.

Preclinical evaluation of the novel CHDI-650 PET ligand for non-invasive quantification of mutant huntingtin aggregates in Huntington's disease

This paper evaluates [18F]CHDI-650, a novel PET radiotracer, for imaging mutant huntingtin aggregates in HD mouse models, showing genotype discrimination at 3 and 9 months.

Benefits of global mutant huntingtin lowering diminish over time in a Huntington's disease mouse model

This study shows that moderate global lowering of mutant Huntingtin in a HD mouse model delays some deficits but benefits diminish over time, suggesting long-term mHtt lowering may be needed for sustained benefit.

A novel imaging ligand as a biomarker for mutant huntingtin-lowering in Huntington's disease

This paper develops a PET radioligand to visualize mutant huntingtin levels in the brain and assess therapeutic interventions in Huntington's disease.